AstraZeneca PLC
NASDAQ:AZN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
61.03
87.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
AstraZeneca PLC
Revenue
AstraZeneca PLC
Revenue Peer Comparison
INDV
HIK
DPH
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
AstraZeneca PLC
NASDAQ:AZN
|
Revenue
$49.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
G
|
GlaxoSmithKline PLC
NYSE:GSK
|
Revenue
£31.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Indivior PLC
LSE:INDV
|
Revenue
$1.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Revenue
$3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Revenue
£761.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Revenue
£183.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
AstraZeneca PLC
Revenue Breakdown
Breakdown by Geography
AstraZeneca PLC
|
Total Revenue:
45.8B
USD
|
|
The Americas:
20.8B
USD
|
|
Asia, Africa And Australasia:
11.9B
USD
|
|
Europe:
9.7B
USD
|
|
China:
5.9B
USD
|
|
Japan:
3.6B
USD
|
|
Uk:
3.4B
USD
|
|
Other, Europe:
3.1B
USD
|
|
Sweden:
1.7B
USD
|
|
France:
1.2B
USD
|
|
Canada:
967m
USD
|
|
Spain:
847m
USD
|
|
Italy:
813m
USD
|
|
Australia:
390m
USD
|
Breakdown by Segments
AstraZeneca PLC
|
Total Revenue:
45.8B
USD
|
|
Total Oncology:
17.1B
USD
|
|
Cvrm:
10.6B
USD
|
|
Rare Disease:
7.8B
USD
|
|
Farxiga:
6B
USD
|
|
Tagrisso:
5.8B
USD
|
|
Imfinzi:
4.2B
USD
|
|
Soliris:
3.1B
USD
|
|
Ultomiris:
3B
USD
|
|
Lynparza:
2.8B
USD
|
|
Calquence:
2.5B
USD
|
|
Symbicort:
2.4B
USD
|
|
Fasenra:
1.6B
USD
|
|
Brilinta:
1.3B
USD
|
|
Total Other Medicines:
1.2B
USD
|
|
Strensiq:
1.2B
USD
|
|
Crestor:
1.1B
USD
|
|
Enhertu:
1B
USD
|
|
Zoladex:
952m
USD
|
|
Nexium:
945m
USD
|
|
Pulmicort:
713m
USD
|
|
Breztri:
677m
USD
|
|
Seloken/Toprol-Xl:
640m
USD
|
|
Synagis:
546m
USD
|
|
Lokelma:
412m
USD
|
|
Koselugo:
331m
USD
|
|
Faslodex:
297m
USD
|
|
Saphnelo:
280m
USD
|
|
Roxadustat:
271m
USD
|
|
Other, Others:
231m
USD
|
|
Onglyza:
227m
USD
|
|
Oncology, Others:
224m
USD
|
|
Flumist:
216m
USD
|
|
Andexxa:
182m
USD
|
|
Kanuma:
171m
USD
|
|
Bydureon:
163m
USD
|
|
Bevespi:
58m
USD
|
|
Daliresp/Daxas:
54m
USD
|
|
Vaxzevria:
12m
USD
|
See Also
What is AstraZeneca PLC's Revenue?
Revenue
49.1B
USD
Based on the financial report for Jun 30, 2024, AstraZeneca PLC's Revenue amounts to 49.1B USD.
What is AstraZeneca PLC's Revenue growth rate?
Revenue CAGR 10Y
6%
Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for AstraZeneca PLC have been 18% over the past three years , 16% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
